
Richard Halperin. And because AIDS makes patients unprotected to microbes that the body can normally defeat, it’s fueling derived illnesses. Hobby.
June 20, 2008June 20 (Bloomberg) — On a bubbly March afternoon, Dennis Burton draws his office blinds, blocking a scrutiny of the 10th tee at La Jolla’s and Southern California’s Pacific surf. Instead, he turns to a small number of twisted, translucent yellow models, each smaller than a bar of soap. This set of what mien like dog chew toys holds the key to Burton’s mission to curb the spread of AIDS, the pandemic that has killed 25 million people in a quarter century and threatens 33 million more today. ”Six or seven years ago, I incontestable that this was what I would be doing the support of my life,” says Burton, 56, seated at a coffee table in his office at the , the world’s largest private, nonprofit inquire into organization. Burton, a British-born biochemist who’s now a professor of immunology at Scripps, leads a lesser who are exploring a mysterious region of the body’s protected system.
His models represent the proteins he says can stop strains of the virus from infecting cells, sparking optimism for a vaccine that would wipe out one of the planet’s most baffling and drug-resistant infections. Betting on a vaccine puts Burton at the center of desire — and contention — in research to marker AIDS, or acquired immune deficiency syndrome. That role has intensified since last September, when pharmaceutical behemoth. suddenly terminated a vaccine trial after inoculated volunteers appeared more liable to to contract HIV, or the human immunodeficiency virus that causes AIDS, than those who got placebo injections. ‘Stick With It’ Now, even after spending billions of dollars since 1984, when U.S. and French researchers announced the finding of HIV, scientists give the word it may be at least 10 more years before another such full of promise vaccine candidate emerges from testing.



BenQ-Siemens